Previous Article | Next Article 
Journal of Virology, April 2000, p. 3037-3045, Vol. 74, No. 7
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Erythroid Cells Rendered Erythropoietin Independent by Infection
with Friend Spleen Focus-Forming Virus Show Constitutive Activation of
Phosphatidylinositol 3-Kinase and Akt Kinase: Involvement of
Insulin Receptor Substrate-Related Adapter Proteins
Kazuo
Nishigaki,1
Charlotte
Hanson,2
Takashi
Ohashi,3
Delores
Thompson,1
Karen
Muszynski,2 and
Sandra
Ruscetti1,*
Basic Research
Laboratory1 and
SAIC-Frederick,2 Frederick Cancer
Research and Development Center, National Cancer Institute, Frederick,
Maryland, and Tokyo Medical and Dental University, Tokyo,
Japan3
Received 26 October 1999/Accepted 4 January 2000
 |
ABSTRACT |
The erythroleukemia-inducing Friend spleen focus-forming virus
(SFFV) encodes a unique envelope glycoprotein which allows erythroid
cells to proliferate and differentiate in the absence of erythropoietin
(Epo). In an effort to understand how SFFV causes Epo independence, we
have been examining erythroid cells rendered factor independent by SFFV
infection for constitutive activation of signal-transducing molecules.
Previous studies from our laboratory showed that various
signal-transducing molecules known to be activated by Epo, including
Stat proteins and components of the Raf-1/MAP kinase pathway, are
constitutively activated in SFFV-infected erythroid cells in the
absence of Epo. Since another signal transduction pathway involving
activation of phosphatidylinositol 3-kinase (PI 3-kinase) after Epo
stimulation plays an important role in erythroid cell proliferation and
differentiation, we carried out studies to determine if this pathway
was also activated in SFFV-infected cells in the absence of Epo. Our
studies show that PI 3-kinase is constitutively activated in erythroid
cells rendered factor independent by infection with SFFV and that PI
3-kinase activity, but not Epo receptor tyrosine phosphorylation, is
required for the proliferation of these cells in the absence of Epo. We
further show that in SFFV-infected erythroid cells grown in the absence of Epo, PI 3-kinase associates with the insulin receptor substrate (IRS)-related adapter molecules IRS-2, Gab1, and Gab2, which are constitutively tyrosine phosphorylated in SFFV-infected cells. Finally,
Akt, a protein kinase that is one of the downstream effectors of PI
3-kinase, and SHIP, a lipid phosphatase that is important for Akt
activation through PI 3-kinase, are both tyrosine phosphorylated in
SFFV-infected cells grown in the absence of Epo. Our results indicate
that induction of Epo independence by SFFV requires the activation of
PI 3-kinase and suggest that constitutive activation of this kinase in
SFFV-infected cells may occur primarily through interaction of PI
3-kinase with constitutively phosphorylated IRS-related adapter molecules.
 |
INTRODUCTION |
The proliferation and
differentiation of erythroid cells are controlled by the binding of
erythropoietin (Epo) to its cell surface receptor, resulting in the
activation of various signal transduction pathways. The major pathways
known to be activated through the Epo receptor (EpoR) are the Jak-Stat
and the Ras/Raf-1/mitogen-activated protein kinase (MAPK) pathways.
When Epo binds to the EpoR, the receptor-bound tyrosine kinase Jak2
becomes rapidly activated (41, 68), most likely through
receptor dimerization (66), and is thought to phosphorylate
itself and tyrosine residues located in the cytoplasmic region of the
EpoR (17, 39). Specific phosphotyrosine residues on the
receptor then serve as docking sites for Stat proteins, in particular
Stat5, which become phosphorylated and translocated to the nucleus
(11, 21, 22, 30, 48, 49, 52, 65). The
tyrosine-phosphorylated sites on the Epo receptor also serve as docking
sites for adapter molecules Shc and Grb2 (3, 9), which link
the receptor to the Ras/Raf-1/MAPK pathway (5, 42, 62). Epo
stimulation also leads to the activation of a third signal transduction
pathway involving the lipid kinase phosphatidylinositol 3-kinase (PI
3-kinase). PI 3-kinase can be activated either through direct binding
of its 85-kDa regulatory subunit to a specific tyrosine-phosphorylated
site on the EpoR (10, 12, 26, 38, 40) or through binding to
insulin receptor substrate (IRS)-related adapter molecules that are
tyrosine phosphorylated after Epo stimulation (35, 63, 67).
Activation of PI 3-kinase leads to the activation of the
serine/threonine kinase Akt (2, 4, 18, 19) and various
isoforms of protein kinase C (1, 44, 46, 61), and recent
studies indicate that this pathway plays an important role in the
proliferation, differentiation, and survival of erythroid progenitor
cells (25, 31).
The Friend spleen focus-forming virus (SFFV) encodes a unique envelope
glycoprotein which allows erythroid cells to proliferate in the absence
of Epo, resulting in the development of erythroleukemia (for a review,
see reference 53). In an attempt to understand how
SFFV alters the growth and differentiation of erythroid cells, we have
been studying signal transduction pathways known to be activated by Epo
to determine if SFFV exerts its biological effects by activating any of
these pathways. We previously showed that SFFV infection leads to the
Epo-independent activation of Stat proteins (48) as well as
the downstream components of the Raf-1/MAPK pathway (45). In
this study, we have focused our investigation on determining the
effects of SFFV infection on the activation of PI 3-kinase and its
downstream effectors. Our results indicate that both PI 3-kinase and
Akt kinase are constitutively activated in SFFV-infected cells growing
in the absence of Epo and that activation of PI 3-kinase, but not EpoR
tyrosine phosphorylation, is required for the Epo-independent
proliferation of SFFV-infected cells. Further studies suggest that PI
3-kinase is constitutively activated in SFFV-infected erythroid cells,
primarily by interaction with the IRS-related adapter molecules IRS-2,
Gab1, and Gab2, all of which are constitutively phosphorylated in these cells.
 |
MATERIALS AND METHODS |
Cell lines.
HCD-57 cells, an Epo-dependent erythroleukemia
cell line (54), were maintained in Iscove's modified
Dulbecco minimal essential medium (IMDM) supplemented with 30% fetal
calf serum (FCS), 5 × 10
5 M 2-mercaptoethanol, and
Epo (0.3 U/ml). HCD-57 cells in which Epo dependence had been abrogated
by infection with either SFFV-P or SFFV-A, two different variants of
SFFV (54), were maintained in the same medium without Epo.
Ba/F3 cells expressing the wild-type EpoR (BaF3/WT-ER) or a mutant EpoR
devoid of intracellular tyrosine residues (BaF3/ZERO-ER)
(20), a generous gift from Patrick Mayeux (Université
Rene Descartes, Paris, France), were maintained in RPMI 1640 medium
supplemented with 10% FCS and Epo (1 U/ml). They were infected with an
amphotropic murine leukemia virus pseudotype of SFFV-P and selected for
Epo independence as previously described (54).
Cell lysates and immunoprecipitation.
To prepare cell
lysates, uninfected and SFFV-infected HCD-57 cells were starved in IMDM
plus 1.5% fetal calf serum for 12 h, while uninfected and
SFFV-infected BaF3/WT-ER and BaF3/ZERO-ER cells were starved in
RPMI 1640 plus 0.5% bovine serum albumin for 7 h. Cells were then
stimulated for various periods of time with 10 U of Epo/ml (or the
concentrations indicated in Fig. 9) or left unstimulated. Cells were
then washed and resuspended in lysis buffer (20 mM Tris-HCl [pH 7.5],
150 mM NaCl, 10% glycerol, 1% Triton X-100, 2 mM EDTA, 0.5 mM
phenylmethylsulfonyl fluoride, 1 mM Na3VO4, 1 µg each of aprotinin and leupeptin/ml). Immunoprecipitations were
performed at 4°C overnight with the following antibodies: anti-IRS-2
(06-506), anti-Gab1 (06-579), anti-Gab2 (06-967), anti-PI 3-kinase p85
(06-195 and 05-212), and antiphosphotyrosine (05-321) (Upstate
Biotechnology, Lake Placid, N.Y.); anti-EpoR (SC-697), anti-SH-PTP2
(SC-280), and anti-SHIP (SC-1964) (Santa Cruz Biotechnology, Santa
Cruz, Calif.); and anti-Shc monoclonal antibody (S14630) (Transduction
Laboratories, Lexington, Ky.). The immune complexes were collected with
protein A-agarose (Upstate Biotechnology) or protein A/G-agarose beads
(Santa Cruz Biotechnology).
Western blot analysis.
Immunoprecipitates were washed three
times with phosphate-buffered saline containing 1% Triton X-100, 0.5%
deoxycholic acid, and 0.1% sodium dodecyl sulfate, resuspended 1:2 in
Laemmli sample buffer, and boiled for 5 min at 100°C.
Immunoprecipitated proteins were separated by electrophoresis on 8%
Tris-glycine minigels (Novex, San Diego, Calif.) and then transferred
electrophoretically to nitrocellulose filters. The filters were
incubated at room temperature for 1 h in blocking buffer (2%
bovine serum albumin in Tris-buffered saline containing 0.2% Tween 20 [TBS-T]), followed by the addition of antiphosphotyrosine antibody
(4G10; 05-321; Upstate Biotechnology) or specific antibodies to Akt
(9272) or to Akt phosphorylated on serine 473 (9270; New England
BioLab, Inc., Beverly, Mass.). After incubation at 4°C overnight, the filters were washed three times with TBS-T and then incubated for 30 min at room temperature with anti-mouse, anti-rabbit, or anti-goat
immunoglobulin G antibody conjugated to horseradish peroxidase
(Amersham Corp. Arlington Heights, Ill.). Blots were washed three times
with TBS-T, and protein bands bound to the antibody were then detected
by enhanced chemiluminescence using the ECL Western blotting analysis
system (Amersham Corp.). In some cases, the filters were stripped and
reprobed with another antibody.
PI 3-kinase assay.
PI 3-kinase activity was assayed as
follows. Immunoprecipitates from cell lysates were washed once in
buffer containing 20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 5 mM EDTA, 1%
Triton X-100, 0.5 mM phenylmethylsulfonyl fluoride, and 1 mM
Na3VO4; once in 20 mM Tris-HCl (pH 7.5)
containing 0.5 M LiCl; and twice in PI 3-kinase buffer (20 mM Tris-HCl
[pH 7.5], 100 mM NaCl, 0.5 mM EGTA). Immunoprecipitates were then
resuspended in PI 3-kinase buffer. Sonicated phosphoinositides (PI)
(Sigma Chemical Corp., St. Louis, Mo.) were added to a final
concentration of 0.2 mg/ml, and phosphorylation was initiated by the
addition of 10 µCi of [
-32P]ATP plus cold ATP and
MgCl2 to final concentrations of 20 µM and 20 mM,
respectively. After incubation at room temperature for 20 min, the
lipids were extracted into chloroform and then methanol-1 N HCl (1:1).
The extracts were then separated on thin-layer chromatography
plates (silica gel 60; Merck, Darmstadt, Germany) in an atmosphere
saturated with chloroform-methanol-NH4OH (28%)-water (215:190:25:35) for 2 h and then visualized by autoradiography. Quantitation of signals after autoradiography was performed by densitometry utilizing NIH-Image software.
Cell proliferation assay.
Uninfected or SFFV-infected HCD-57
cells were starved in IMDM containing 1.5% FCS for 12 h and then
resuspended in medium containing 20% FCS with or without Epo (0.3 U/ml) and with or without PI 3-kinase inhibitor LY294002 (various
concentrations; Sigma). Cells were then plated at a concentration of
5 × 104 cells/well in 96-well microtiter plates and
incubated for 24 h before the addition of the cell proliferation
reagent WST-1 (Boehringer GmbH, Mannheim, Germany). After incubation
for 4 h in a humidified atmosphere, the absorbances of the samples
were measured at 450 nm against background controls using an
enzyme-linked immunosorbent assay reader. Relative proliferation was
determined as a percentage by dividing the absorbance in the presence
of inhibitor by the absorbance in the absence of inhibitor and
multiplying by 100. Uninfected and SFFV-infected BaF3/WT-ER and
BaF3/ZERO-ER cells were plated at a concentration of 104
cells/well in RPMI 1640 medium plus 10% FCS with or without Epo at
various concentrations. After incubation for 72 h, WST-1 was added
for 4 h and the absorbance was measured as described above. Relative proliferation of each line was determined as a percentage by
dividing the absorbance for each point by the absorbance obtained when
the cells were grown in 0.36 U of Epo/ml and multiplying by 100.
 |
RESULTS |
PI 3-kinase is constitutively activated in SFFV-infected erythroid
cells.
It has previously been demonstrated that PI 3-kinase is
activated in erythroid cells in response to Epo. In order to determine if PI 3-kinase is constitutively activated in SFFV-infected cells, Epo-dependent HCD-57 cells or HCD-57 cells that had been rendered factor independent following infection with SFFV were left unstimulated or were stimulated with Epo for various amounts of time. Cell lysates
were then immunoprecipitated with antiphosphotyrosine antibody, and PI
3-kinase activity was determined by an in vitro kinase assay using PI
as a substrate. As shown in Fig. 1, there is a very low level of PI 3-kinase activity in unstimulated HCD-57 cells and it is greatly increased (13-fold) within 5 min after Epo
stimulation. In contrast, HCD-57 cells infected with SFFV showed a high
level of PI 3-kinase activation even in the absence of Epo stimulation.

View larger version (23K):
[in this window]
[in a new window]
|
FIG. 1.
PI 3-kinase is constitutively activated in SFFV-infected
erythroid cells. Uninfected or SFFV-infected HCD-57 cells were left
unstimulated or were stimulated with Epo for the indicated periods of
time. Cell lysates were then immunoprecipitated (IP) with
antiphosphotyrosine ( PY) antibody. PI 3-kinase activity was
determined by an in vitro kinase assay using PI as a substrate. PI
phosphate (PIP) was separated by thin-layer chromatography, and the
plate was exposed to film for 24 h. PI 3-kinase activity was
quantitated, and the results were expressed as fold activation relative
to that for unstimulated HCD-57 cells.
|
|
Association of the 85-kDa regulatory subunit of PI 3-kinase with
tyrosine-phosphorylated proteins in SFFV-infected cells grown in the
absence of Epo.
PI 3-kinase can be activated after Epo stimulation
by direct association of its 85-kDa regulatory unit with
tyrosine-phosphorylated EpoR molecules (10, 12, 26, 38, 40)
or by association with one of the tyrosine-phosphorylated IRS adapter
molecules IRS-2 (63), Gab1 (35, 67), and Gab2
(67). In order to examine the tyrosine-phosphorylated
proteins associated with constitutively activated PI 3-kinase in
SFFV-infected cells, we precipitated extracts of these cells with
antiserum to PI 3-kinase p85 and then carried out Western blotting with
antiphosphotyrosine antibodies. As shown in Fig.
2, Epo stimulation of both uninfected and
SFFV-infected HCD-57 cells resulted in the association of PI 3-kinase
with a number of tyrosine-phosphorylated proteins, including those with molecular masses of 180, 97, 78, and 57 kDa. These proteins were subsequently identified as IRS-2, Gab1 or -2, EpoR, and Shc,
respectively (data not shown). In SFFV-infected cells grown in the
absence of Epo, the p85 regulatory subunit of PI 3-kinase specifically associated with several of these tyrosine-phosphorylated proteins, but
not detectably with the 78-kDa protein corresponding to the EpoR. We
failed to detect tyrosine phosphorylation of the EpoR in SFFV-infected
cells unless they were stimulated with Epo (data not shown), and that
may explain our failure to detect its association with the p85 subunit
of PI 3-kinase in the absence of Epo. Although PI 3-kinase does not
appear to directly bind to tyrosine-phosphorylated EpoR molecules in
SFFV-infected cells grown in the absence of Epo, it does appear to be
associated with the EpoR complexes in these cells. As shown in Fig. 2B,
we were able to detect constitutive PI 3-kinase activity in lysates
from SFFV-infected HCD-57 cells, but not from uninfected HCD-57 cells,
after immunoprecipitation with antiserum to the EpoR.

View larger version (57K):
[in this window]
[in a new window]
|
FIG. 2.
Association of PI 3-kinase p85 with
tyrosine-phosphorylated proteins and detection of PI 3-kinase activity
in the EpoR complex in SFFV-infected HCD-57 cells in the absence of
Epo. (A) Uninfected and SFFV-infected HCD-57 cells were left
unstimulated or were stimulated with Epo for the indicated periods of
time. PI 3-kinase p85-associated proteins were detected by
immunoprecipitation (IP) with anti-p85 antiserum, followed by
immunoblotting with antiphosphotyrosine ( PY) or anti-p85 antiserum.
(B) Anti-EpoR immunoprecipitates were tested for PI 3-kinase activity
by an in vitro PI 3-kinase assay using PI as a substrate. PI phosphate
(PIP) was separated by thin-layer chromatography, and the plate was
exposed to film for 24 h. PI 3-kinase activity was quantitated,
and the results were expressed as fold activation relative to that for
unstimulated HCD-57 cells.
|
|
IRS-2, Gab1, and Gab2 are constitutively phosphorylated in
SFFV-infected cells and associate with PI 3-kinase activity.
Since
our data indicated that tyrosine-phosphorylated proteins corresponding
in molecular weight to the IRS-related adapter proteins IRS-2, Gab1,
and Gab2 were constitutively associated with the regulatory subunit of
PI 3-kinase in SFFV-infected cells, we carried out further studies with
specific antisera to these adapter molecules to determine if the
activation of PI 3-kinase that occurs in SFFV-infected cells in the
absence of Epo is primarily mediated through these adapter molecules.
As shown in Fig. 3A, uninfected HCD-57
cells show a low level of constitutive IRS-2 tyrosine phosphorylation,
perhaps due to the presence of insulin or insulin-like growth factors
in the medium, and this level is greatly increased after Epo
stimulation. The level of IRS-2 tyrosine phosphorylation was not
increased by stimulation of HCD-57 cells with stem cell factor (data
not shown). However, HCD-57 cells infected with SFFV show a
significantly higher level of IRS-2 tyrosine phosphorylation in the
absence of Epo than uninfected HCD-57 cells. To determine if the
tyrosine-phosphorylated IRS-2 present in SFFV-infected cells in the
absence of Epo was involved in the constitutive activation of PI
3-kinase in these cells, we carried out an in vitro PI 3-kinase assay
using immunoprecipitates from cell lysates treated with an antiserum
specific for IRS-2. As shown in Fig. 3B, a low level of PI 3-kinase
activity associates with IRS-2 in uninfected HCD-57 cells before Epo
stimulation and this level is greatly increased (approximately
fivefold) after the cells are exposed to Epo for 5 min. In contrast,
SFFV-infected HCD-57 cells showed high levels of IRS-2-associated PI
3-kinase activity in the absence of Epo stimulation.

View larger version (70K):
[in this window]
[in a new window]
|
FIG. 3.
IRS-2 is tyrosine phosphorylated in SFFV-infected
erythroid cells in the absence of Epo and constitutively associates
with PI 3-kinase. Uninfected and SFFV-infected HCD-57 cells were left
unstimulated or were stimulated with Epo for the indicated periods of
time. (A) IRS-2 was detected by immunoprecipitation (IP) with
anti-IRS-2 antiserum followed by blotting with antiphosphotyrosine
( PY) or anti-IRS-2 antibodies. (B) Anti-IRS-2 immunoprecipitates
were tested for PI 3-kinase activity by an in vitro PI 3-kinase assay
using PI as a substrate. PI phosphate (PIP) was separated by thin-layer
chromatography, and the plate was exposed to film for 24 h. PI
3-kinase activity was quantitated, and the results were expressed as
fold activation relative to that for unstimulated HCD-57 cells.
|
|
SFFV-infected cells show constitutive phosphorylation of, in addition
to IRS-2, the related adapter molecules Gab1 and Gab2.
As shown in Fig.
4A, Gab1 is tyrosine phosphorylated in
uninfected
HCD-57 cells only after Epo stimulation but is
constitutively
phosphorylated in SFFV-infected cells in the absence of
Epo. Furthermore,
as shown in Fig.
4B, Gab1 immunoprecipitates from
SFFV-infected
cells grown in the absence of Epo contained significantly
more
PI 3-kinase activity (4- to 14-fold) than immunoprecipitates from
uninfected HCD-57 cells, where PI 3-kinase activity was
negligible
in the absence of Epo. Gab2 is also tyrosine phosphorylated
in
uninfected HCD-57 cells after Epo stimulation (Fig.
5A), but,
like Gab1, it is constitutively
phosphorylated in SFFV-infected
HCD-57 cells. Furthermore, as shown in
Fig.
5B, Gab2 constitutively
associates with PI 3-kinase activity in
SFFV-infected HCD-57 cells,
whereas it does not significantly associate
with PI 3-kinase in
uninfected HCD-57 cells unless the cells are
stimulated with Epo.

View larger version (64K):
[in this window]
[in a new window]
|
FIG. 4.
Gab1 is tyrosine phosphorylated in SFFV-infected
erythroid cells in the absence of Epo and constitutively associates
with PI 3-kinase activity. Uninfected and SFFV-infected HCD-57 cells
were left unstimulated or were stimulated with Epo for the indicated
periods of time. (A) Tyrosine-phosphorylated Gab1, total Gab1, and
Gab1-associated SHP-2 were detected by immunoprecipitation (IP) of cell
lysates with antiserum to Gab1, followed by immunoblotting with either
antiphosphotyrosine ( PY), anti-Gab1, or anti-SHP-2 antibodies. (B)
Anti-Gab1 immunoprecipitates were tested for PI 3-kinase activity by
an in vitro PI 3-kinase assay using PI as a substrate. PI
phosphate (PIP) was separated by thin-layer chromatography, and the
plate was exposed to film for 24 h. PI 3-kinase activity was
quantitated, and the results were expressed as fold activation relative
to that for unstimulated HCD-57 cells.
|
|

View larger version (46K):
[in this window]
[in a new window]
|
FIG. 5.
Gab2 is tyrosine phosphorylated in SFFV-infected
erythroid cells in the absence of Epo and constitutively associates
with PI 3-kinase activity. Uninfected and SFFV-infected HCD-57 cells
were left unstimulated or were stimulated with Epo for the indicated
periods of time. (A) Tyrosine-phosphorylated Gab2, total Gab2, and
Gab2-associated SHP-2 were detected by immunoprecipitation (IP) of cell
lysates with antiserum to Gab2, followed by immunoblotting with either
antiphosphotyrosine ( PY), anti-Gab2, or anti-SHP-2 antibodies. (B)
Anti-Gab2 immunoprecipitates were tested for PI 3-kinase activity by an
in vitro PI 3-kinase assay using PI as a substrate. PI phosphate (PIP)
was separated by thin-layer chromatography, and the plate was exposed
to film for 48 h. PI 3-kinase activity was quantitated, and the
results were expressed as fold activation relative to that for
unstimulated HCD-57 cells.
|
|
Previous studies have shown that the protein tyrosine phosphatase SHP-2
associates with tyrosine-phosphorylated Gab1 and Gab2
after stimulation
with certain growth factors, resulting in the
tyrosine phosphorylation
of SHP-2 (
35,
47,
58,
67). As
shown in Fig.
4A and
5A, SHP-2
becomes tyrosine phosphorylated
and associates with Gab1 and Gab2
in both uninfected and SFFV-infected
HCD-57 cells after Epo
stimulation. However, Epo-independent tyrosine
phosphorylation of
SHP-2 and its association with Gab1 and Gab2
can only be detected in
SFFV-infected HCD-57 cells. The same results
were obtained when
anti-SHP-2 immunoprecipitates were examined
(data not shown). In
addition to SHP-2, Shc is also coprecipitated
with Gab1 and Gab2, both
in response to Epo and constitutively
in SFFV-infected cells (note the
57-kDa tyrosine-phosphorylated
proteins in Fig.
4A and
5A).
Inhibition of PI 3-kinase activity blocks Epo-independent
proliferation of SFFV-infected cells.
In order to determine if
activation of PI 3-kinase is required for the Epo-independent
proliferation of SFFV-infected cells, we studied the effect of the
specific PI 3-kinase inhibitor LY294002 (64) on the
proliferation of uninfected and SFFV-infected HCD-57 cells. As shown in
Fig. 6, treatment with LY294002 of both
uninfected and SFFV-infected HCD-57 cells growing in the presence of
Epo resulted in a dose-dependent inhibition of proliferation at doses that are known to block PI 3-kinase activity. Importantly, the Epo-independent proliferation of SFFV-infected cells was severely inhibited by the drug (reduced by 94 to 95% at 40 µM), even more than was the Epo-dependent proliferation of uninfected HCD-57 cells
(reduced by 72% at 40 µM). These results demonstrate that the
Epo-independent proliferation of SFFV-infected cells is dependent on PI
3-kinase activation.

View larger version (34K):
[in this window]
[in a new window]
|
FIG. 6.
PI 3-kinase activity is required for the Epo-independent
proliferation of SFFV-infected erythroid cells. Uninfected or
SFFV-infected HCD-57 cells were grown with or without Epo for 24 h
in medium containing various concentrations of the PI 3-kinase
inhibitor LY294002. The level of cell proliferation was measured as
described in Materials and Methods. Relative proliferation was
determined as a percentage by comparing proliferation of the cells in
the presence of the drug with proliferation in its absence. The
means ± standard deviations of triplicate measurements are shown.
The levels of proliferation of the cell lines in the absence of the
drug were similar (relative proliferation levels were 1 for uninfected
HCD-57 cells, 1.2 for SFFV-A-infected HCD-57 cells, and 1.5 for
SFFV-P-infected HCD-57 cells). Uninfected HCD-57 cells, in the absence
as well as in the presence of inhibitor, failed to proliferate unless
Epo was added (data not shown).
|
|
Akt kinase and the lipid phosphatase SHIP are tyrosine
phosphorylated after Epo stimulation and SFFV infection.
The
protein kinase Akt is a downstream effector of activated PI 3-kinase in
many systems, and it was recently shown to be activated in response to
Epo (2). In order to determine if this kinase is
constitutively activated in SFFV-infected cells, cell lysates were
immunoblotted with an antiserum that specifically detects Akt
phosphorylated on serine 473. As shown in Fig.
7, a very low level of phosphorylated Akt
is detected in uninfected HCD-57 in the absence of Epo but the addition
of Epo leads to a significant increase, with maximum levels of
phosphorylated protein detected after a 30-min stimulation. In
contrast, HCD-57 cells infected with SFFV express high levels of
phosphorylated Akt in the absence of Epo, indicating that Akt is
constitutively phosphorylated in SFFV-infected cells.

View larger version (17K):
[in this window]
[in a new window]
|
FIG. 7.
Akt kinase is constitutively phosphorylated in
SFFV-infected erythroid cells in the absence of Epo. Uninfected or
SFFV-infected HCD-57 cells were left unstimulated or stimulated with 10 U of Epo/ml for the indicated periods of time. Cell lysates were then
immunoblotted with either anti-phospho-Akt (Ser 473) or anti-Akt
antiserum.
|
|
It has previously been shown that Akt is activated by only one of the
three lipid products of PI 3-kinase, phosphatidylinositol
3,4-bisphosphate (
19,
32). The levels of this product are
thought to be regulated by specific inositol polyphosphate
5'-phosphatases
such as SIP and SHIP (
13,
29). Since SHIP is
tyrosine phosphorylated
in response to Epo (
13), we examined
HCD-57 cells and their
virus-infected counterparts for the tyrosine
phosphorylation of
SHIP in the presence or absence of Epo. As shown in
Fig.
8, SHIP
is activated by tyrosine
phosphorylation in uninfected HCD-57
cells only after Epo stimulation
but is phosphorylated in SFFV-infected
HCD-57 cells in the absence of
Epo. Furthermore, SHIP can be coimmunoprecipitated
with PI 3-kinase and
Gab1 both after Epo stimulation and in SFFV-infected
cells grown in the
absence of Epo (data not shown).

View larger version (48K):
[in this window]
[in a new window]
|
FIG. 8.
SHIP is constitutively phosphorylated in SFFV-infected
cells. Uninfected and SFFV-infected HCD-57 cells were left unstimulated
or stimulated with Epo for the indicated periods of time. Cell lysates
were then immunoprecipitated (IP) with antiserum to SHIP, followed by
immunoblotting with antiphosphotyrosine ( PY) or anti-SHIP
antiserum.
|
|
Induction of Epo independence by SFFV does not require EpoR
tyrosine phosphorylation.
Activation of PI 3-kinase in erythroid
cells can occur either by the direct binding of PI 3-kinase to
phosphorylated tyrosine sites on the EpoR or by its binding to
tyrosine-phosphorylated IRS-related adapter molecules, and our data
suggest that activation of PI 3-kinase by SFFV occurs primarily by its
binding to IRS adapter molecules. In order to determine if SFFV could
render cells factor independent in the absence of EpoR tyrosine
phosphorylation, we took advantage of a cell line expressing a mutant
EpoR devoid of intracellular tyrosines. This line, designated
BaF3/ZERO-ER (20), expresses an EpoR that lacks the last 109 amino acids and that contains a mutation of Tyr343 to Phe.
As shown in Fig. 9, BaF3/ZERO-ER cells
proliferate in response to Epo, but less efficiently than a line
expressing the wild-type EpoR (BaF3/WT-ER). When BaF3/WT-ER and
BaF3/ZERO-ER cells were infected with SFFV-P, they were both
rendered factor independent and proliferated to high levels in the
absence of Epo (Fig. 9). Further analysis of the Epo-independent
SFFV-infected BaF3/ZERO-ER cells indicated that PI 3-kinase was
constitutively associated in these cells with high levels of
tyrosine-phosphorylated proteins corresponding to Gab proteins
and IRS-2 (Fig. 10A). Like SFFV-infected HCD-57 cells, BaF3/WT-ER and BaF3/ZERO-ER cells rendered factor independent by SFFV showed constitutive tyrosine phosphorylation of both Gab1 (Fig. 10B) and Gab2 (Fig. 10C) and the
constitutive association of SHP-2 with these adapter molecules. Thus,
SFFV can induce Epo independence as well as the constitutive activation
of IRS adapter proteins and their association with PI 3-kinase in cells
expressing truncated EpoR molecules lacking intracellular tyrosine
residues.

View larger version (16K):
[in this window]
[in a new window]
|
FIG. 9.
Induction of Epo independence by SFFV does not require
EpoR tyrosine phosphorylation. Ba/F3 cells expressing wild-type EpoR
(WT) or a mutant EpoR that contains no intracellular tyrosine residues
(ZERO) were infected with SFFV-P, and Epo-independent clones were
selected and designated WT/SFFV and ZERO/SFFV. Cells were grown without
Epo or with various concentrations of Epo for 72 h, and the level
of proliferation was measured as described in Materials and Methods.
Relative proliferation was determined as a percentage of the absorbance
at each point relative to the absorbance when the cells were grown in
0.36 U of Epo/ml.
|
|

View larger version (39K):
[in this window]
[in a new window]
|
FIG. 10.
Phosphorylation of IRS adapter molecules and their
association with PI 3-kinase do not require EpoR tyrosine
phosphorylation. Uninfected or SFFV-infected BaF3/WT-ER or BaF3/ZERO-ER
cells were left unstimulated or stimulated with Epo for 20 min. (A) PI
3-kinase p85-associated proteins were detected by immunoprecipitation
(IP) of cell lysates with anti-p85 antiserum followed by immunoblotting
with antiphosphotyrosine ( PY) or anti-p85 antiserum. ZERO,
uninfected BaF3/ZERO-ER cells; ZERO/SFFVp, BaF3/ZERO-ER cells infected
with SFFV-P. (B) Tyrosine-phosphorylated Gab1, total Gab1, and
Gab1-associated SHP-2 were detected by immunoprecipitation of cell
lysates with antiserum to Gab1, followed by immunoblotting with either
antiphosphotyrosine, anti-Gab1, or anti-SHP-2 antibodies. WT,
uninfected BaF3/WT-ER cells; WT/SFFVp, BaF3/WT-ER cells infected with
SFFV-P. (C) Tyrosine-phosphorylated Gab2, total Gab2, and
Gab2-associated SHP-2 were detected by immunoprecipitation of cell
lysates with antiserum to Gab2, followed by immunoblotting with either
antiphosphotyrosine, anti-Gab2, or anti-SHP-2 antibodies.
|
|
 |
DISCUSSION |
Previous studies from our laboratory have shown that infection of
erythroid cells with the erythroleukemia-inducing Friend SFFV leads to
the Epo-independent activation of components of the Jak-Stat and the
Raf-1/MAPK pathways. In this study we show that PI 3-kinase is also
constitutively activated in SFFV-infected erythroid cells and that its
activity is required for the Epo-independent proliferation of these
cells. We further show that both the Epo-independent proliferation of
SFFV-infected cells and the activation of PI 3-kinase in these cells
can occur in the absence of EpoR tyrosine phosphorylation and involves
the activation of IRS-related adapter molecules. Finally, we
demonstrate that Akt kinase, one of the downstream targets of PI
3-kinase, is also constitutively activated in SFFV-infected cells.
PI 3-kinase, which is rapidly activated in response to Epo, plays an
essential role in the proliferation and differentiation of normal
erythroid cells (10, 12, 25, 26, 28, 31, 38, 40). PI
3-kinase can be activated by Epo in one of several ways. The regulatory
subunit of the kinase, p85, can bind directly to tyrosine 479 in the
carboxyl terminus of the EpoR after it has been tyrosine phosphorylated
in response to Epo (12). Alternatively, p85 can bind to
adapter molecules, such as IRS-2 (63), Gab1 (35,
67), and Gab2 (67), which become tyrosine
phosphorylated after Epo stimulation. It is not known which of these
mechanisms is primarily used by erythroid cells to activate PI 3-kinase
in response to Epo, although it is likely that maximum proliferation occurs when both of these mechanisms are intact. In contrast to Epo-induced activation of PI 3-kinase, Epo-independent activation of PI
3-kinase in SFFV-infected erythroid cells appears to occur primarily
through activation of IRS-related adapter molecules. When we examined
SFFV-infected erythroid cells, we were unable to detect the association
of PI 3-kinase with tyrosine-phosphorylated EpoR proteins unless Epo
was present, although PI 3-kinase activity could be immunoprecipitated
with antiserum to the EpoR, indicating that PI 3-kinase activity was
associated with the EpoR complex. In contrast, we could clearly detect
the association of PI 3-kinase with the tyrosine-phosphorylated adapter
molecules IRS-2, Gab1, and Gab2 in SFFV-infected erythroid cells grown
in the absence of Epo. These IRS-related adapter molecules, which are
tyrosine phosphorylated in normal erythroid cells only after Epo
stimulation, are constitutively tyrosine phosphorylated in
SFFV-infected erythroid cells, and PI 3-kinase activity could be
immunoprecipitated with antisera specific to each of these adapter
molecules. Thus, the Epo-independent activation of PI 3-kinase in
SFFV-infected cells appears to be mediated preferentially through the
binding of PI 3-kinase to tyrosine-phosphorylated IRS adapter molecules
associated with the EpoR complex rather than through its direct binding
to tyrosine-phosphorylated sites on the EpoR. This idea is supported by
the fact that a hematopoietic cell line that expresses mutant EpoRs
devoid of intracellular tyrosine residues, including the PI 3-kinase
binding site, could be rendered factor independent after infection with
SFFV. Importantly, PI 3-kinase constitutively associates with IRS
adapter molecules in these cells, and Gab1 and Gab2 are constitutively
phosphorylated. Thus, induction of Epo independence and activation of
the PI 3-kinase pathway by SFFV do not require the phosphorylation of
intracellular tyrosine residues in the EpoR.
The physiological relevance of constitutive activation of PI 3-kinase
in SFFV-infected cells is demonstrated by the fact that we can
completely inhibit the Epo-independent proliferation of these cells
using low concentrations of LY294002, a specific inhibitor of PI
3-kinase. Interestingly, the Epo-independent proliferation of
SFFV-infected HCD-57 cells was more sensitive to low doses of the PI
3-kinase inhibitor than that of uninfected HCD-57 cells or of
SFFV-infected HCD-57 cells grown in the presence of Epo. This suggests
that the Epo-independent growth of SFFV-infected cells is more
dependent on activation of the PI 3-kinase pathway than the
Epo-dependent growth of normal erythroid cells. Thus, it may be
possible to use low concentrations of PI 3-kinase inhibitors to
specifically block the proliferation of SFFV-infected erythroid cells
in vivo without inhibiting the growth of normal cells.
For these studies, we examined HCD-57 cells infected with two different
variants of SFFV: SFFV-P and SFFV-A. Although infection of HCD-57 cells
with these variants does not cause any obvious difference in biological
phenotype, infection of primary erythroid cells demonstrates that
SFFV-P and SFFV-A have different effects on the growth and
differentiation of erythroid cells (for a review, see reference
53). Cells infected with SFFV-P can both proliferate and differentiate in the absence of Epo, while those infected with
SFFV-A still require Epo for differentiation and are hypersensitive to
Epo for proliferation. It is, therefore, interesting to note that
HCD-57 cells infected with SFFV-A, either in the absence or presence of
Epo, consistently show higher levels of tyrosine-phosphorylated IRS-related adapter molecules and constitutive PI 3-kinase activity than cells infected with SFFV-P. Furthermore, SFFV-A-infected HCD-57
cells are more sensitive than SFFV-P-infected cells to growth
inhibition by low doses of the PI 3-kinase inhibitor LY294002. The
biological differences between these two variants are attributed to a
subtle difference in the transmembrane regions of their envelope glycoproteins (7, 8), and this may alter how the viral
proteins interact with the EpoR and, consequently, the signals that
emanate from the receptor to control cell growth and differentiation. For example, interaction of the SFFV-A envelope glycoprotein, but not
that of SFFV-P, with the EpoR may block the binding of a negative
regulatory factor, allowing the cells to become hypersensitive to both
Epo and SFFV and leading to higher levels of PI 3-kinase activity and
higher levels of other signal-transducing molecules. Higher levels of
PI 3-kinase may be required for the Epo-independent activation of cell
proliferation by SFFV-A-infected cells because interaction of the
SFFV-A envelope glycoprotein with the EpoR may be unable to activate a
complementary signal transduction pathway activated by SFFV-P. This may
explain why SFFV-A-infected HCD-57 cells are more sensitive to growth
inhibition by low doses of the PI 3-kinase inhibitor LY294002.
Our previous studies showed that components of the Raf-1/MAPK pathway
are constitutively activated in SFFV-infected cells (45),
and this may be mediated by the activation of the IRS/PI 3-kinase
pathway. In SFFV-infected erythroid cells, we observed the constitutive
association of Gab1 and Gab2 with SHP-2, Shc, and SHIP, and formation
of such multimolecular complexes could lead to the activation of Ras
and the Raf-1/MAPK pathway (3, 47, 58, 59). Alternatively,
MEK or MAPK may be directly phosphorylated in SFFV-infected cells by
one of the isoforms of protein kinase C (16, 23, 31),
another downstream effector of PI 3-kinase that we find constitutively
activated in SFFV-infected cells (unpublished data). We also detect
constitutive activation of Stat proteins in SFFV-infected erythroid
cells (48), but it is unclear whether this is also mediated
by activation of the IRS/PI 3-kinase pathway. In normal erythroid
cells, Stat proteins are primarily activated after binding to specific
tyrosine-phosphorylated sites on the EpoR, but they can also be
activated at low levels in the absence of EpoR tyrosine phosphorylation
(11, 21, 30), and this may occur by the direct binding of
Stat proteins to phosphorylated IRS-related adapter molecules. However,
we have been unable to detect the association of IRS-related adapter
proteins with Stat proteins in SFFV-infected cells either in the
absence or presence of Epo (data not shown).
It is not known how IRS-2, Gab1, and Gab2 become tyrosine
phosphorylated in SFFV-infected HCD-57 cells grown in the absence of
Epo. Epo stimulation leads to the activation of the tyrosine kinase
Jak2 (41, 68), and it has been suggested that Jak kinases may phosphorylate IRS adapter molecules in other systems (58, 70). However, we have been unable to detect the constitutive phosphorylation of Jak2 or of any other Epo-induced kinase, including Fes, Lyn, and Tec (6, 24, 37, 60), in SFFV-infected cells (data not shown). Since interaction of the SFFV envelope glycoprotein with the EpoR may lead to activation of a tyrosine kinase not activated
by Epo, we are also examining SFFV-infected cells for the constitutive
activation of other tyrosine kinases. We have failed to detect the
constitutive activation of Jak1, Jak3, or Tyk-2 (data not shown) and
are currently examining SFFV-infected erythroid cells for the
constitutive activation of Stk, a receptor tyrosine kinase that
was recently implicated in susceptibility to SFFV-induced
erythroleukemia (50).
In addition to demonstrating that PI 3-kinase is constitutively
activated in SFFV-infected cells, we also show that one of its
downstream targets, the serine/threonine kinase Akt (4, 18,
19), is also constitutively activated in SFFV-infected cells
grown in the absence of Epo. Our studies further suggest that
activation of Akt by PI 3-kinase is promoted by the constitutive activation in these virus-infected cells of the lipid phosphatase SHIP,
whose activity leads to the generation of phospholipid products known
to specifically activate Akt (19, 32). Activation of Akt is
thought to promote cell survival by blocking apoptosis, primarily
thorough phosphorylation of BAD (14, 15), a Bcl-2 family
member whose death-promoting function is inactivated by phosphorylation. It is not known whether any Bcl-2 family members are
phosphorylated in response to Epo. However, the levels of Bcl-2 and
Bcl-XL dramatically drop after Epo withdrawal (2, 27,
56), suggesting that these Bcl-2 family members are the primary
repressors of apoptosis in erythroid cells. Studies are, therefore, in
progress to determine if BAD or any other Bcl-2 family members are
phosphorylated or altered in expression level in SFFV-infected cells
grown in the absence of Epo.
This study provides strong evidence that induction of Epo independence
in vitro by SFFV is mediated by the constitutive activation of the PI
3-kinase/Akt pathway and suggests that deregulation of this pathway in
vivo may be a critical step in the development of SFFV-induced
erythroleukemia in mice. Recent studies have suggested that
constitutive activation of the PI 3-kinase/Akt pathway may also play an
important role in the development of hematopoietic malignancies and
solid tumors in humans. Chronic myelogeneous leukemia and acute
lymphoblastic leukemia associated with activation of the Bcr/Abl
oncogene are associated with activation of the PI 3-kinase/Akt pathway
(57), and PI 3-kinase or Akt or both have been shown to be
constitutively activated, or their levels enhanced, in a number of
solid human tumors (33, 43, 51, 55). IRS-2 has also been
shown to be overexpressed in human pancreatic cancer cell lines
(34), and this may lead to deregulation of the PI
3-kinase/Akt pathway in these cells. In many of these studies,
inhibitors of PI 3-kinase have been shown to block the proliferation of
the malignant cells, suggesting that constitutive activation of the PI
3-kinase pathway is critical for tumor cell growth. Consistent with
this idea are recent studies showing that the tumor suppressor gene
PTEN functions as a negative regulator of the PI 3-kinase/Akt pathway
and that mutations in this gene can increase susceptibility to cancer
(36, 69). Thus, constitutive activation of the PI
3-kinase/Akt pathway may be a common event leading to leukemia and
cancer, making it an attractive target for therapeutic intervention.
 |
ACKNOWLEDGMENTS |
We thank Karen Cannon and Angelo Spadaccini for helpful
assistance in the preparation of the manuscript and Patrick Mayeux for
generously providing the BaF3/ZERO-ER cell line.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Basic Research
Laboratory, Bldg. 469, Room 205, NCI-FCRDC, Frederick, MD 21702-1201. Phone: (301) 846-5740. Fax: (301) 846-6164. E-mail:
ruscetti{at}ncifcrf.gov.
 |
REFERENCES |
| 1.
|
Akimoto, K.,
R. Takahashi,
S. Moriya,
N. Nishioka,
J. Takayanagi,
K. Kimura,
Y. Fukui,
S. Osada,
K. Mizuno,
S. Hirai,
A. Kazlauskas, and S. Ohno.
1996.
EGF or PDGF receptors activate atypical PKC through phosphatidylinositol 3-kinase.
EMBO J.
15:788-798[Medline].
|
| 2.
|
Bao, H.,
S. M. Jacobs-Helber,
A. E. Lawson,
K. Penta,
A. Wickrema, and S. T. Sawyer.
1999.
Protein kinase B (c-Akt), phosphatidylinositol 3-kinase, and STAT5 are activated by erythropoietin (EPO) in HCD57 erythroid cells but are constitutively active in an EPO-independent, apoptosis-resistant subclone (HCD57-SREI cells).
Blood
93:3757-3773[Abstract/Free Full Text].
|
| 3.
|
Barber, D. L.,
C. N. Corless,
K. Xia,
T. M. Roberts, and A. D. D'Andrea.
1997.
Erythropoietin activates Raf1 by an Shc-independent pathway in CTLL-EPO-R cells.
Blood
89:55-64[Abstract/Free Full Text].
|
| 4.
|
Boudewijn, B. M., and P. J. Coffer.
1995.
Protein kinase B (c-Akt) in phosphatidylinositol 3-OH kinase signal transduction.
Nature
376:599-602[CrossRef][Medline].
|
| 5.
|
Carroll, M. P.,
J. L. Spivak,
M. McMahon,
N. Weich, and U. F. Rapp.
1991.
Erythropoietin induces Raf-1 activation and Raf-1 is required for erythropoietin-mediated proliferation.
J. Biol. Chem.
266:14964-14969[Abstract/Free Full Text].
|
| 6.
|
Chin, H.,
A. Arai,
H. Wakao,
R. Kamiyama,
N. Miyasaka, and O. Miura.
1998.
Lyn physically associates with the erythropoietin receptor and may play a role in activation of the Stat5 pathway.
Blood
91:3734-3745[Abstract/Free Full Text].
|
| 7.
|
Chung, S. W.,
L. Wolff, and S. Ruscetti.
1989.
Transmembrane domain of the envelope gene of a polycythemia-inducing retrovirus determines erythropoietin-independent growth.
Proc. Natl. Acad. Sci. USA
86:7957-7960[Abstract/Free Full Text].
|
| 8.
|
Constanthinescu, S.,
X. Liu,
W. Beyer,
A. Fallon,
S. Shekar,
Y. I. Henis,
S. O. Smith, and H. F. Lodish.
1999.
Activation of the erythropoietin receptor by the gp55-P viral envelope protein is determined by a single amino acid in its transmembrane domain.
EMBO J.
18:3334-3347[CrossRef][Medline].
|
| 9.
|
Damen, J. E.,
L. Liu,
R. L. Cutler, and G. Krystal.
1993.
Erythropoietin stimulates the tyrosine phosphorylation of Shc and its association with Grb2 and a 145-Kd tyrosine phosphorylated protein.
Blood
82:2296-2303[Abstract/Free Full Text].
|
| 10.
|
Damen, J. E.,
A. L.-F. Mui,
L. Puil,
T. Pawson, and G. Krystal.
1993.
Phosphatidylinositol 3-kinase associates, via its Src homology 2 domains, with the activated erythropoietin receptor.
Blood
81:3204-3210[Abstract/Free Full Text].
|
| 11.
|
Damen, J. E.,
H. Wakao,
A. Miyajima,
J. Krosl,
R. K. Humphries,
R. L. Cutler, and G. Krystal.
1995.
Tyrosine 343 in the erythropoietin receptor positively regulates erythropoietin-induced cell proliferation and Stat5 activation.
EMBO J.
14:5557-5568[Medline].
|
| 12.
|
Damen, J. E.,
R. L. Cutler,
H. Jiao,
T. Yi, and G. Krystal.
1995.
Phosphorylation of tyrosine 503 in the erythropoietin receptor (EpR) is essential for binding the P85 subunit of phosphatidylinositol (PI) 3-kinase and for EpR-associated PI 3-kinase activity.
J. Biol. Chem.
270:23402-23408[Abstract/Free Full Text].
|
| 13.
|
Damen, J. E.,
L. Liu,
P. Rosten,
R. K. Humphries,
A. B. Jefferson,
P. W. Majerus, and G. Krystal.
1996.
The 145-kDa protein induced to associate with Shc by multiple cytokines is an inositol tetraphosphate and phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase.
Proc. Natl. Acad. Sci. USA
93:1689-1693[Abstract/Free Full Text].
|
| 14.
|
Datta, S. R.,
H. Dudek,
X. Tao,
S. Masters,
H. Fu,
Y. Gotoh, and M. E. Greenberg.
1997.
Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery.
Cell
91:231-241[CrossRef][Medline].
|
| 15.
|
Del Peso, L.,
M. Gonzalez-Garcia,
C. Page,
R. Herrera, and G. Nunez.
1997.
Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt.
Science
278:687-689[Abstract/Free Full Text].
|
| 16.
|
Devemy, E.,
C. Billat, and B. Haye.
1997.
Activation of Raf-1 and mitogen-activated proteins kinases by erythropoietin and inositolphosphate-glycan in normal and erythroid progenitor cells: involvement of protein kinase C.
Cell. Signal.
9:41-46[CrossRef][Medline].
|
| 17.
|
Dusanter-Fourt, I. N. C.,
C. Lacombe,
O. Muller,
C. Billat,
S. Fischer, and P. Mayeux.
1992.
Erythropoietin induces the tyrosine phosphorylation of its own receptor in human erythropoietin-responsive cells.
J. Biol. Chem.
267:10670-10675[Abstract/Free Full Text].
|
| 18.
|
Franke, T. F.,
S. I. Yang,
T. O. Chan,
K. Datta,
A. Kazlauskas,
D. K. Morrison,
D. R. Kaplan, and P. N. Tsichlis.
1995.
The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase.
Cell
81:727-736[CrossRef][Medline].
|
| 19.
|
Franke, T. F.,
D. R. Kaplan,
L. C. Cantley, and A. Toker.
1997.
Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate.
Science
275:665-668[Abstract/Free Full Text].
|
| 20.
|
Gobert, S.,
F. Porteu,
S. Pallu,
O. Muller,
M. Sabbah,
I. Dusanter-Fourt,
G. Courtois,
C. Lacombe,
S. Gisselbrecht, and P. Mayeux.
1995.
Tyrosine phosphorylation of the erythropoietin receptor: role for differentiation and mitogenic signal transduction.
Blood
86:598-606[Abstract/Free Full Text].
|
| 21.
|
Gobert, S.,
S. Chretien,
F. Gouilleux,
O. Muller,
C. Pallard,
I. Dusanter-Fourt,
B. Groner,
C. Lacombe,
S. Gisselbrecht, and P. Mayeux.
1996.
Identification of tyrosine residues within the intracellular domain of the erythropoietin receptor crucial for STAT5 activation.
EMBO J.
15:2434-2441[Medline].
|
| 22.
|
Gouilleux, F.,
C. Pallard,
I. Dusanter-Fourt,
H. Wakao,
L.-A. Haldosen,
G. Norstedt,
D. Levy, and B. Groner.
1995.
Prolactin, growth hormone, erythropoietin and granulocyte-macrophage colony stimulating factor induce MGF-Stat5 DNA binding activity.
EMBO J.
14:2005-2013[Medline].
|
| 23.
|
Grammar, T. C., and J. Blenis.
1997.
Evidence for MEK-independent pathways regulating the prolonged activation of the ERK-MAP kinases.
Oncogene
14:1635-1642[CrossRef][Medline].
|
| 24.
|
Hanazono, Y.,
S. Chiba,
K. Sasaki,
H. Mano,
Y. Yazaki, and H. Hirai.
1993.
Erythropoietin induces tyrosine phosphorylation and kinase activity of the c-fps/fes proto-oncogene product in human erythropoietin-responsive cells.
Blood
81:3193-3196[Abstract/Free Full Text].
|
| 25.
|
Haseyama, Y.,
K. Sawada,
A. Oda,
K. Koizumi,
H. Takano,
T. Tarumi,
M. Nishio,
M. Handa,
Y. Ikeda, and T. Koike.
1999.
Phosphatidylinositol 3-kinase is involved in the protection of primary cultured human erythroid precursor cells from apoptosis.
Blood
94:1568-1577[Abstract/Free Full Text].
|
| 26.
|
He, T. C.,
H. Zhuang,
N. Jiang,
M. D. Waterfield, and D. M. Wojchowski.
1993.
Association of the p85 regulatory subunit of phosphatidylinositol 3-kinase with an essential erythropoietin receptor subdomain.
Blood
82:3530-3538[Abstract/Free Full Text].
|
| 27.
|
Jacobs-Helber, S. M.,
A. Wickrema,
M. J. Birrer, and S. T. Sawyer.
1998.
AP1 regulation of proliferation and initiation of apoptosis in erythropoietin-dependent erythroid cells.
Mol. Cell. Biol.
18:3699-3707[Abstract/Free Full Text].
|
| 28.
|
Jaster, R.,
T. Bittorf, and J. Brock.
1997.
Involvement of phosphatidylinositol 3-kinase in the mediation of erythropoietin-induced activation of p70S6k.
Cell. Signal.
9:175-179[CrossRef][Medline].
|
| 29.
|
Kavanaugh, W.,
M. D. A. Pot,
S. M. Chin,
M. Deuter-Reinhard,
A. B. Jefferson,
F. A. Norris,
F. R. Masiarz,
L. S. Cousens,
P. W. Majerus, and L. T. Williams.
1996.
Multiple forms of an inositol polyphosphate-5-phosphatase form signaling complexes with Shc and Grb2.
Curr. Biol.
6:438-445[CrossRef][Medline].
|
| 30.
|
Klingmüller, U.,
S. Bergelson,
J. G. Hsiao, and H. F. Lodish.
1996.
Multiple tyrosine residues in the cytosolic domain of the erythropoietin receptor promote activation of STAT5.
Proc. Natl. Acad. Sci. USA
93:8324-8328[Abstract/Free Full Text].
|
| 31.
|
Klingmüller, U.,
H. Wu,
J. G. Hsiao,
A. Toker,
B. C. Duckworth,
L. C. Cantley, and H. F. Lodish.
1997.
Identification of a novel pathway important for proliferation and differentiation of primary erythroid progenitors.
Proc. Natl. Acad. Sci. USA
94:3016-3021[Abstract/Free Full Text].
|
| 32.
|
Klippel, A.,
W. M. Kavanaugh,
D. Pot, and L. T. Williams.
1997.
A specific product of phosphatidylinositol 3-kinase directly activates the protein kinase Akt through its pleckstrin homology domain.
Mol. Cell. Biol.
17:338-344[Abstract].
|
| 33.
|
Kobayashi, M.,
S. Nagata,
T. Iwasaki,
K. Yanagihara,
I. Saitoh,
Y. Karouji,
S. Ihara, and Y. Fukui.
1999.
Dedifferentiation of adenocarcinomas by activation of phosphatidylinositol 3-kinase.
Proc. Natl. Acad. Sci. USA
96:4874-4879[Abstract/Free Full Text].
|
| 34.
|
Kornmann, M.,
H. Maruyama,
U. Bergmann,
P. Tangvoranuntakul,
H. G. Beger,
M. F. White, and M. Korc.
1998.
Enhanced expression of the insulin receptor substrate-2 docking protein in human pancreatic cancer.
Cancer Res.
58:4250-4254[Abstract/Free Full Text].
|
| 35.
|
Lecoq-Lafon, C.,
F. Verdier,
S. Fichelson,
S. Chretien,
S. Gisselbrecht,
C. Lacombe, and P. Mayeux.
1999.
Erythropoietin induces the tyrosine phosphorylation of GAB1 and its association with SHC, SHP2 and phosphatidylinositol 3-kinase.
Blood
93:2578-2585[Abstract/Free Full Text].
|
| 36.
|
Li, D. M., and H. Sun.
1998.
PTEN/MMAC1/TEP1 suppresses the tumorigenicity and induces G1 cell cycle arrest in human glioblastoma cells.
Proc. Natl. Acad. Sci. USA
95:15406-15411[Abstract/Free Full Text].
|
| 37.
|
Machide, M.,
H. Mano, and K. Todokoro.
1995.
Interleukin 3 and erythropoietin induce association of Vav with Tec kinase through Tec homology domain.
Oncogene
11:619-625[Medline].
|
| 38.
|
Mayeux, P.,
I. Dusanter-Fourt,
O. Muller,
P. Mauduit,
M. Sabbah,
B. Druker,
W. Vainchenker,
S. Fischer,
C. Lacombe, and S. Gisselbrecht.
1993.
Erythropoietin induces the association of phosphatidylinositol 3'-kinase with a tyrosine-phosphorylated complex containing the erythropoietin receptor.
Eur. J. Biochem.
216:821-828[Medline].
|
| 39.
|
Miura, O.,
A. D'Andrea,
D. Kabat, and J. N. Ihle.
1991.
Induction of tyrosine phosphorylation by the erythropoietin receptor correlates with mitogenesis.
Mol. Cell. Biol.
11:4895-4902[Abstract/Free Full Text].
|
| 40.
|
Miura, O.,
N. Nakamura,
J. N. Ihle, and N. Aoki.
1994.
Erythropoietin-dependent association of phosphatidylinositol 3-kinase with tyrosine-phosphorylated erythropoietin receptor.
J. Biol. Chem.
269:614-620[Abstract/Free Full Text].
|
| 41.
|
Miura, O.,
N. Nakamura,
F. W. Quelle,
B. A. Witthuhn,
J. N. Ihle, and N. Aoki.
1994.
Erythropoietin induces association of the JAK2 protein tyrosine kinase with the erythropoietin receptor in vivo.
Blood
84:1501-1507[Abstract/Free Full Text].
|
| 42.
|
Miura, Y.,
O. Miura,
J. N. Ihle, and N. Aoki.
1994.
Activation of the mitogen-activated protein kinase pathway by the erythropoietin receptor.
J. Biol. Chem.
269:29962-29969[Abstract/Free Full Text].
|
| 43.
|
Moore, S. M.,
R. C. Rintoul,
T. R. Walker,
E. R. Chilvers,
C. Haslett, and T. Sethi.
1998.
The presence of a constitutively active phosphoinositide 3-kinase in small cell lung cancer cells mediates anchorage-independent proliferation via a protein kinase B and p70s6k-dependent pathway.
Cancer Res.
15:5239-5247.
|
| 44.
|
Moriya, S.,
A. Kazlauskas,
K. Akimoto,
S.-I. Hirai,
K. Mizuno,
T. Takenawa,
Y. Fukui,
Y. Watanabe,
S. Ozaki, and S. Ohno.
1996.
Platelet-derived growth factor activates protein kinase C through redundant and independent signaling pathways involving phospholipase C or phosphatidylinositol 3-kinase.
Proc. Natl. Acad. Sci. USA
93:151-155[Abstract/Free Full Text].
|
| 45.
|
Muszynski, K. W.,
T. Ohashi,
C. Hanson, and S. K. Ruscetti.
1998.
Both the polycythemia- and anemia-inducing strains of Friend spleen focus-forming virus induce constitutive activation of the Raf-1 mitogen-activated protein kinase signal transduction pathway.
J. Virol.
72:919-925[Abstract/Free Full Text].
|
| 46.
|
Nakanishi, H.,
K. A. Brewer, and J. H. Exton.
1993.
Activation of the enzyme of protein kinase C by phosphatidylinositol 3,4,5-trisphosphate.
J. Biol. Chem.
268:13-16[Abstract/Free Full Text].
|
| 47.
|
Nishida, K.,
Y. Yoshida,
M. Itoh,
T. Fukada,
T. Ohtani,
T. Shirogane,
T. Atsumi,
M. Takahashi-Tezuka,
K. Ishihara,
M. Hibi, and T. Hirano.
1999.
Gab-family adapter proteins act downstream of cytokine and growth factor receptors and T- and B-cell antigen receptors.
Blood
93:1809-1816[Abstract/Free Full Text].
|
| 48.
|
Ohashi, T.,
M. Masuda, and S. K. Ruscetti.
1995.
Induction of sequence-specific DNA-binding factors by erythropoietin and the spleen focus-forming virus.
Blood
85:1454-1462[Abstract/Free Full Text].
|
| 49.
|
Penta, K., and S. T. Sawyer.
1995.
Erythropoietin induces the tyrosine phosphorylation, nuclear translocation, and DNA binding of STAT1 and STAT5 in erythroid cells.
J. Biol. Chem.
270:31282-31287[Abstract/Free Full Text].
|
| 50.
|
Persons, D. A.,
R. F. Paulson,
M. R. Loyd,
M. T. Herley,
S. M. Bodner,
A. Bernstein,
P. H. Correll, and P. A. Ney.
1999.
Fv2 encodes a truncated form of the Stk receptor tyrosine kinase.
Nat. Genet.
23:159-165[CrossRef][Medline].
|
| 51.
|
Phillips, W. A.,
F. St. Clair,
A. D. Munday,
R. J. Thomas, and C. A. Mitchell.
1998.
Increased levels of phosphatidylinositol 3-kinase activity in colorectal tumors.
Cancer
1:41-47.
|
| 52.
|
Quelle, F. W.,
D. Wang,
T. Nosaka,
W. E. Thierfelder,
D. Stravopodis,
Y. Weinstein, and J. N. Ihle.
1996.
Erythropoietin induces the activation of STAT5 through association with specific tyrosines on the receptor that are not required for a mitogenic response.
Mol. Cell. Biol.
16:1622-1631[Abstract].
|
| 53.
|
Ruscetti, S. K.
1999.
Deregulation of erythropoiesis by the Friend spleen focus-forming virus.
Int. J. Biochem. Cell Biol.
31:10-35.
|
| 54.
|
Ruscetti, S. K.,
N. J. Janesch,
A. Chakraborti,
S. T. Sawyer, and W. D. Hankins.
1990.
Friend spleen focus-forming virus induces factor independence in an erythropoietin-dependent erythroleukemia cell line.
J. Virol.
64:1057-1062[Abstract/Free Full Text].
|
| 55.
|
Shayesteh, L.,
Y. Lu,
W. L. Kuo,
R. Baldocchi,
T. Godfrey,
C. Collins,
D. Pinkel,
B. Powell,
G. B. Mills, and J. W. Gray.
1999.
PIK3CA is implicated as an oncogene in ovarian cancer.
Nat. Genet.
21:64-65[CrossRef][Medline].
|
| 56.
|
Silva, M.,
D. Grillot,
A. Benito,
C. Richard,
G. Nuñez, and J. L. Fernández-Luna.
1996.
Erythropoietin can promote erythroid progenitor survival by repressing apoptosis through Bcl-X1 and Bcl-2.
Blood
88:1576-1582[Abstract/Free Full Text].
|
| 57.
|
Skorski, T.,
A. Bellacosa,
M. Nieborowska-Skorska,
M. Majewski,
R. Martinez,
J. K. Choi,
R. Trotta,
P. Wlodarski,
D. Perrotti,
T. O. Chan,
M. A. Wasik,
P. N. Tsichlis, and B. Calabretta.
1997.
Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway.
EMBO
16:6151-6161[CrossRef][Medline].
|
| 58.
|
Takahashi-Tezuka, M.,
Y. Yoshida,
T. Fukada,
T. Ohtani,
Y. Yamanaka,
K. Nishida,
K. Nakajima,
M. Hibi, and T. Hirano.
1998.
Gab1 acts as an adapter molecule linking the cytokine receptor gp130 to ERK mitogen-activated protein kinase.
Mol. Cell. Biol.
18:4109-4117[Abstract/Free Full Text].
|
| 59.
|
Tauchi, T.,
G.-S. Feng,
R. Shen,
M. Hoatlin,
G. C. Bagby, Jr.,
D. Kabat,
L. Lu, and H. E. Broxmeyer.
1995.
Involvement of SH2-containing phosphotyrosine phosphatase Syp in erythropoietin receptor signal transduction pathways.
J. Biol. Chem.
270:5631-5635[Abstract/Free Full Text].
|
| 60.
|
Tilbrook, P. A.,
E. Ingley,
J. H. Williams,
M. L. Hibbs, and S. P. Klinken.
1997.
Lyn tyrosine kinase is essential for erythropoietin-induced differentiation of J2E erythroid cells.
EMBO J.
16:1610-1619[CrossRef][Medline].
|
| 61.
|
Toker, A.,
M. Meyer,
K. K. Reddy,
J. R. Falck,
R. Aneja,
S. Aneja,
A. Parra,
D. J. Burns,
L. M. Ballas, and L. C. Cantley.
1994.
Activation of protein kinase C family members by the novel polyphosphoinositides PtdIns-3,4-P2 and PtdIns-3,4,5-P3.
J. Biol. Chem.
269:32358-32367[Abstract/Free Full Text].
|
| 62.
|
Torti, M.,
K. B. Marti,
D. Altshuler,
K. Yamamoto, and E. G. Lapetina.
1992.
Erythropoietin induces p21ras activation and p120GAP tyrosine phosphorylation in human erythroleukemia cells.
J. Biol. Chem.
267:8293-8298[Abstract/Free Full Text].
|
| 63.
|
Verdier, F.,
S. Chrétien,
C. Billat,
S. Gisselbrecht,
C. Lacombe, and P. Mayeux.
1997.
Erythropoietin induces the tyrosine phosphorylation of insulin receptor substrate-2.
J. Biol. Chem.
272:26173-26178[Abstract/Free Full Text].
|
| 64.
|
Vlahos, C. J.,
W. F. Matter,
K. Y. Hui, and R. F. Brown.
1994.
A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002).
J. Biol. Chem.
269:5241-5248[Abstract/Free Full Text].
|
| 65.
|
Wakao, H.,
N. Harada,
T. Kitamura,
A. L.-F. Mui, and A. Miyajima.
1995.
Interleukin 2 and erythropoietin activate STAT5/MGF via distinct pathways.
EMBO J.
11:2527-2535.
|
| 66.
|
Watowich, S. S.,
D. J. Hilton, and H. F. Lodish.
1994.
Activation and inhibition of erythropoietin receptor function: role of receptor dimerization.
Mol. Cell. Biol.
14:3535-3549[Abstract/Free Full Text].
|
| 67.
|
Wickrema, A.,
S. Uddin,
A. Sharma,
F. Chen,
Y. Alsayed,
S. Ahmad,
S. T. Sawyer,
G. Krystal,
T. Yi,
K. Nishada,
M. Hibi,
T. Hirano, and L. C. Platanias.
1999.
Engagement of Gab1 and Gab2 in erythropoietin signaling.
J. Biol. Chem.
274:24469-24474[Abstract/Free Full Text].
|
| 68.
|
Witthuhn, B. A.,
F. W. Quelle,
O. Silvennoinen,
T. Yi,
B. Tang,
O. Miura, and J. N. Ihle.
1993.
JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin.
Cell
74:227-236[CrossRef][Medline].
|
| 69.
|
Wu, X.,
K. Senechal,
M. S. Neshat,
Y. E. Whang, and C. L. Sawyers.
1998.
The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway.
Proc. Natl. Acad. Sci. USA
95:15587-15591[Abstract/Free Full Text].
|
| 70.
|
Yamauchi, T.,
Y. Kaburagi,
K. Ueki,
Y. Tsuji,
G. R. Stark,
I. M. Kerr,
T. Tsushima,
Y. Akanuma,
I. Komuro,
K. Tobe,
Y. Yazaki, and T. Kadowaki.
1998.
Growth hormone and prolactin stimulate tyrosine phosphorylation of insulin receptor substrate-1, -2, and -3, their association with p85 phosphatidylinositol 3-kinase (PI 3-kinase), and concomitantly PI 3-kinase activation via JAK2 kinase.
J. Biol. Chem.
273:15719-15726[Abstract/Free Full Text].
|
Journal of Virology, April 2000, p. 3037-3045, Vol. 74, No. 7
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Grech, G., Blazquez-Domingo, M., Kolbus, A., Bakker, W. J., Mullner, E. W., Beug, H., von Lindern, M.
(2008). Igbp1 is part of a positive feedback loop in stem cell factor-dependent, selective mRNA translation initiation inhibiting erythroid differentiation. Blood
112: 2750-2760
[Abstract]
[Full Text]
-
Sathyanarayana, P., Dev, A., Fang, J., Houde, E., Bogacheva, O., Bogachev, O., Menon, M., Browne, S., Pradeep, A., Emerson, C., Wojchowski, D. M.
(2008). EPO receptor circuits for primary erythroblast survival. Blood
111: 5390-5399
[Abstract]
[Full Text]
-
Jelacic, T. M., Thompson, D., Hanson, C., Cmarik, J. L., Nishigaki, K., Ruscetti, S.
(2008). The Tyrosine Kinase sf-Stk and Its Downstream Signals Are Required for Maintenance of Friend Spleen Focus-Forming Virus-Induced Fibroblast Transformation. J. Virol.
82: 419-427
[Abstract]
[Full Text]
-
Rimmele, P., Kosmider, O., Mayeux, P., Moreau-Gachelin, F., Guillouf, C.
(2007). Spi-1/PU.1 participates in erythroleukemogenesis by inhibiting apoptosis in cooperation with Epo signaling and by blocking erythroid differentiation. Blood
109: 3007-3014
[Abstract]
[Full Text]
-
Nishigaki, K., Hanson, C., Ohashi, T., Spadaccini, A., Ruscetti, S.
(2006). Erythroblast Transformation by the Friend Spleen Focus-Forming Virus Is Associated with a Block in Erythropoietin-Induced STAT1 Phosphorylation and DNA Binding and Correlates with High Expression of the Hematopoietic Phosphatase SHP-1.. J. Virol.
80: 5678-5685
[Abstract]
[Full Text]
-
Brown, L., Benchimol, S.
(2006). The Involvement of MAPK Signaling Pathways in Determining the Cellular Response to p53 Activation: CELL CYCLE ARREST OR APOPTOSIS. J. Biol. Chem.
281: 3832-3840
[Abstract]
[Full Text]
-
Zhao, W., Kitidis, C., Fleming, M. D., Lodish, H. F., Ghaffari, S.
(2006). Erythropoietin stimulates phosphorylation and activation of GATA-1 via the PI3-kinase/AKT signaling pathway. Blood
107: 907-915
[Abstract]
[Full Text]
-
Nishigaki, K., Hanson, C., Jelacic, T., Thompson, D., Ruscetti, S.
(2005). Friend spleen focus-forming virus transforms rodent fibroblasts in cooperation with a short form of the receptor tyrosine kinase Stk. Proc. Natl. Acad. Sci. USA
102: 15488-15493
[Abstract]
[Full Text]
-
Nishigaki, K., Hanson, C., Thompson, D., Yugawa, T., Ruscetti, S.
(2005). Activation of the Jun N-Terminal Kinase Pathway by Friend Spleen Focus-Forming Virus and Its Role in the Growth and Survival of Friend Virus-Induced Erythroleukemia Cells. J. Virol.
79: 12752-12762
[Abstract]
[Full Text]
-
Joosten, M., Blazquez-Domingo, M., Lindeboom, F., Boulme, F., Van Hoven-Beijen, A., Habermann, B., Lowenberg, B., Beug, H., Mullner, E. W., Delwel, R., Von Lindern, M.
(2004). Translational Control of Putative Protooncogene Nm23-M2 by Cytokines via Phosphoinositide 3-Kinase Signaling. J. Biol. Chem.
279: 38169-38176
[Abstract]
[Full Text]
-
Rulli, K., Yugawa, T., Hanson, C., Thompson, D., Ruscetti, S., Nishigaki, K.
(2004). Ex Vivo and In Vivo Biological Effects of a Truncated Form of the Receptor Tyrosine Kinase Stk When Activated by Interaction with the Friend Spleen Focus-Forming Virus Envelope Glycoprotein or by Point Mutation. J. Virol.
78: 4573-4581
[Abstract]
[Full Text]
-
Huddleston, H., Tan, B., Yang, F.-C., White, H., Wenning, M. J., Orazi, A., Yoder, M. C., Kapur, R., Ingram, D. A.
(2003). Functional p85{alpha} gene is required for normal murine fetal erythropoiesis. Blood
102: 142-145
[Abstract]
[Full Text]
-
Tefferi, A.
(2003). Polycythemia Vera: A Comprehensive Review and Clinical Recommendations. Mayo Clin Proc.
78: 174-194
[Abstract]
-
Lin, Y., Brown, L., Hedley, D. W., Barber, D. L., Benchimol, S.
(2002). The death-promoting activity of p53 can be inhibited by distinct signaling pathways. Blood
100: 3990-4000
[Abstract]
[Full Text]
-
Alberti, A., Murgia, C., Liu, S.-L., Mura, M., Cousens, C., Sharp, M., Miller, A. D., Palmarini, M.
(2002). Envelope-Induced Cell Transformation by Ovine Betaretroviruses. J. Virol.
76: 5387-5394
[Abstract]
[Full Text]
-
Thomas, K. W., Monick, M. M., Staber, J. M., Yarovinsky, T., Carter, A. B., Hunninghake, G. W.
(2002). Respiratory Syncytial Virus Inhibits Apoptosis and Induces NF-kappa B Activity through a Phosphatidylinositol 3-Kinase-dependent Pathway. J. Biol. Chem.
277: 492-501
[Abstract]
[Full Text]
-
Palmarini, M., Maeda, N., Murgia, C., De-Fraja, C., Hofacre, A., Fan, H.
(2001). A Phosphatidylinositol 3-Kinase Docking Site in the Cytoplasmic Tail of the Jaagsiekte Sheep Retrovirus Transmembrane Protein Is Essential for Envelope-Induced Transformation of NIH 3T3 Cells. J. Virol.
75: 11002-11009
[Abstract]
[Full Text]
-
Palmarini, M., Fan, H.
(2001). Retrovirus-Induced Ovine Pulmonary Adenocarcinoma, an Animal Model for Lung Cancer. JNCI J Natl Cancer Inst
93: 1603-1614
[Abstract]
[Full Text]
-
Barnache, S., Mayeux, P., Payrastre, B., Moreau-Gachelin, F.
(2001). Alterations of the phosphoinositide 3-kinase and mitogen-activated protein kinase signaling pathways in the erythropoietin-independent Spi-1/PU.1 transgenic proerythroblasts. Blood
98: 2372-2381
[Abstract]
[Full Text]
-
Nishigaki, K., Thompson, D., Hanson, C., Yugawa, T., Ruscetti, S.
(2001). The Envelope Glycoprotein of Friend Spleen Focus-Forming Virus Covalently Interacts with and Constitutively Activates a Truncated Form of the Receptor Tyrosine Kinase Stk. J. Virol.
75: 7893-7903
[Abstract]
[Full Text]
-
Somervaille, T. C. P., Linch, D. C., Khwaja, A.
(2001). Growth factor withdrawal from primary human erythroid progenitors induces apoptosis through a pathway involving glycogen synthase kinase-3 and Bax. Blood
98: 1374-1381
[Abstract]
[Full Text]
-
Maeda, N., Palmarini, M., Murgia, C., Fan, H.
(2001). Direct transformation of rodent fibroblasts by jaagsiekte sheep retrovirus DNA. Proc. Natl. Acad. Sci. USA
98: 4449-4454
[Abstract]
[Full Text]
-
Muszynski, K. W., Thompson, D., Hanson, C., Lyons, R., Spadaccini, A., Ruscetti, S. K.
(2000). Growth Factor-Independent Proliferation of Erythroid Cells Infected with Friend Spleen Focus-Forming Virus Is Protein Kinase C Dependent but Does Not Require Ras-GTP. J. Virol.
74: 8444-8451
[Abstract]
[Full Text]
-
Miyakawa, Y., Rojnuckarin, P., Habib, T., Kaushansky, K.
(2001). Thrombopoietin Induces Phosphoinositol 3-Kinase Activation through SHP2, Gab, and Insulin Receptor Substrate Proteins in BAF3 Cells and Primary Murine Megakaryocytes. J. Biol. Chem.
276: 2494-2502
[Abstract]
[Full Text]